Enrollment rate is a fairly standard type of measurement in clinical research. However, the number of factors that affect enrollment rates, and the ways they interact, are anything but simple. Sponsors can set clear recruitment goals and select thoughtful study systems to aid sites, and yet trials continue to fall short. Understanding the various factors that impact enrollment rates, and why so many studies struggle to reach their enrollment targets, is the first step toward building an effective recruitment strategy.
What Is a Clinical Trial Enrollment Rate?
Clinical trial enrollment rate is a metric used to measure the speed at which eligible participants are successfully recruited and enrolled in a study within a set timeframe (e.g., number of participants enrolled per month at a site).
A strong enrollment rate reflects effective site selection, participant outreach, and study design. A low rate, by contrast, often signals systemic barriers: overly restrictive eligibility criteria, limited site capacity, or insufficient support for recruitment staff.
What Percentage of Clinical Trials Fail to Meet Enrollment Goals?
The numbers are striking. According to 2024 WCG Data Intelligence:
- 85 percent of trials fail to recruit enough participants.
- 80 percent of trials fail to meet their enrollment targets on time.
- The average number of targeted endpoints has increased by 37 percent, adding considerable pressure to already strained recruitment timelines.
These percentages represent the reality of how complex clinical research has become across therapeutic areas and phases. As protocols increase the number of procedures, amendments, criteria, and endpoints, the eligible participant pool shrinks and the burden for participants and sites grows, widening the gap between enrollment goals and actual performance.
Key Enrollment Rate Benchmarks: By Phase and Outcome
The table below outlines how enrollment performance varies by study phase and site performance level.
| Factor | Lower-Performing Trials | Higher-Performing Trials |
|---|---|---|
| Sites meeting enrollment goals | < 50 percent | ≥ 70 percent |
| Time to first participant enrolled | ≥ Six months post-activation | ≤ Three months post-activation |
| Sites enrolling any participant | Around 85% | Close to 100% |
| Study timeline extension due to enrollment | Common (1 – 3 months or more) | Rare |
Note: These benchmarks draw from WCG Data Intelligence and general industry patterns. Individual trial performance will vary by indication, protocol complexity, and site support.
What Factors Have the Biggest Impact on Clinical Trial Enrollment Rates?
Several variables affect whether a trial meets its enrollment targets:
- Protocol Complexity: As the number of targeted endpoints increases, eligibility windows narrow and participant and protocol burden grows.
- Site Selection: Sites without sufficient patient populations or research infrastructure routinely under-enroll. According to the Tufts Center for Drug Development (2023), 37 percent of sites under-enroll.
- Recruitment Support: Sites often lack the bandwidth to find and pre-screen participants alongside their clinical workload. Those with centralized recruitment and retention support tailored to their patient population consistently outperform those without.
- Study Start-Up Delays: WCG’s 2026 Clinical Research Site Challenges Report data showed sites reported budget development and negotiations (56%), sponsor/CRO engagement and responsiveness (43%), and CTA negotiation (38%) as the top three challenges affecting their start-up timelines.
Best Practices for Improving Enrollment
Sponsors and contract research organizations (CROs) that consistently hit enrollment targets share a few common approaches:
- Invest in site feasibility early. Selecting sites with strong patient populations and research infrastructure reduces the risk of under-enrollment before the trial begins.
- Use data to forecast realistically. Benchmark analytics tools can model enrollment timelines based on historical site performance, indication, and geography, helping teams set achievable goals.
- Deploy tailored recruitment support. Generic outreach rarely works. Site-level recruitment strategies, built around each site’s workflows and patient referral networks, are far more effective.
- Monitor and adapt in real time. Waiting for quarterly reports to identify enrollment problems can provide insights too late. Continuous visibility into site performance allows teams to intervene before delays compound.
Frequently Asked Questions
A high-performing clinical trial reaches 100 percent of the targeted enrollment within the planned timeline. In practice, trials that enroll 70 percent or more of their target on schedule are considered to be performing well. Trials that fall below 50 percent often require protocol amendments, timeline extensions, or additional site activations.
The primary causes include overly complex protocols with high participant burden, poor site selection, limited recruitment infrastructure, and insufficient ongoing support for sites during trial conduct.
Greater protocol complexity typically means stricter eligibility criteria and more participant visits, both of which reduce the eligible pool, increase participant burden, and subsequently increase dropout risk.
Based on study data from WCG’s Data Intelligence, a one-month delay in a non-oncology clinical trial equals approximately $2.3 million in lost productivity and extended operating costs.
Sponsors can improve enrollment rates by investing in thorough site feasibility analysis, deploying centralized recruitment and retention support, using benchmark analytics to set realistic timelines, and maintaining real-time visibility into site performance.
How WCG Supports On-Time Enrollment
Most enrollment support, when provided, is delivered across multiple sites at a scale too large to address the persistent root causes impacting enrollment and retention. If sponsors and CROs want to measurably improve enrollment rates, they first need to understand what’s slowing enrollment down, whether that’s overly strict inclusion/exclusion criteria, a high number of visits, or complex procedures. WCG’s Study Acceleration Solutions cuts through the surface-level signals to identify the underlying issues, deploy targeted solutions to effectively address the problems, and sustainably carry forward those changes to avoid future barriers.
It’s also important to partner with a site that is poised to successfully carry out the study based on its capacity, geographical location, available participant populations, and level of staff support. WCG’s Site Network connects sponsors and CROs with a diverse network of high-performing sites to make sure the right study finds the right site.
Learn how WCG can support your enrollment processes by filling out the form below to connect with one of our experts.
Ready to Accelerate Study Performance?
Talk with our team about how Study Acceleration Solutions helps identify and address execution barriers early, apply targeted support where it matters most, and maintain study momentum from startup through database lock.